Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis

Tom Kovitwanichkanont, Sudha Raghunath, Dorothy Wang, Leo Kyi, Silvana Pignataro, Susan Morton, Eric Morand, Michelle Leech

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)


Biosimilars are increasingly adopted to improve affordability of biologics. An effective introduction of biosimilars requires an understanding of patient acceptance of these agents. We performed a cross-sectional study of 132 patients with rheumatoid arthritis prior to the introduction of biosimilar switching or prescribing in this cohort. Despite being unfamiliar with biosimilars, most patients are willing to accept biosimilar medicines if recommended by their rheumatologist. Patient concerns about biosimilar uptake mainly focus on concerns about its efficacy. There is a significant correlation between patient attitudes towards biosimilar and generic medicines.

Original languageEnglish
Pages (from-to)374-377
Number of pages4
JournalInternal Medicine Journal
Issue number3
Publication statusPublished - Mar 2020


  • biologic
  • biosimilar
  • etanercept
  • generic medicine
  • health economics
  • public health

Cite this